Literature DB >> 19343044

Molecular karyotyping in 17 patients and mutation screening in 41 patients with Kabuki syndrome.

Hideo Kuniba1, Koh-ichiro Yoshiura, Tatsuro Kondoh, Hirofumi Ohashi, Kenji Kurosawa, Hidefumi Tonoki, Toshiro Nagai, Nobuhiko Okamoto, Mitsuhiro Kato, Yoshimitsu Fukushima, Tadashi Kaname, Kenji Naritomi, Tadashi Matsumoto, Hiroyuki Moriuchi, Tatsuya Kishino, Akira Kinoshita, Noriko Miyake, Naomichi Matsumoto, Norio Niikawa.   

Abstract

The Kabuki syndrome (KS, OMIM 147920), also known as the Niikawa-Kuroki syndrome, is a multiple congenital anomaly/mental retardation syndrome characterized by a distinct facial appearance. The cause of KS has been unidentified, even by whole-genome scan with array comparative genomic hybridization (CGH). In recent years, high-resolution oligonucleotide array technologies have enabled us to detect fine copy number alterations. In 17 patients with KS, molecular karyotyping was carried out with GeneChip 250K NspI array (Affymetrix) and Copy Number Analyser for GeneChip (CNAG). It showed seven copy number alterations, three deleted regions and four duplicated regions among the patients, with the exception of registered copy number variants (CNVs). Among the seven loci, only the region of 9q21.11-q21.12 (approximately 1.27 Mb) involved coding genes, namely, transient receptor potential cation channel, subfamily M, member 3 (TRPM3), Kruppel-like factor 9 (KLF9), structural maintenance of chromosomes protein 5 (SMC5) and MAM domain containing 2 (MAMDC2). Mutation screening for the genes detected 10 base substitutions consisting of seven single-nucleotide polymorphisms (SNPs) and three silent mutations in 41 patients with KS. Our study could not show the causative genes for KS, but the locus of 9q21.11-q21.12, in association with a cleft palate, may contribute to the manifestation of KS in the patient. As various platforms on oligonucleotide arrays have been developed, higher resolution platforms will need to be applied to search tiny genomic rearrangements in patients with KS.

Entities:  

Mesh:

Year:  2009        PMID: 19343044     DOI: 10.1038/jhg.2009.30

Source DB:  PubMed          Journal:  J Hum Genet        ISSN: 1434-5161            Impact factor:   3.172


  14 in total

Review 1.  International Union of Basic and Clinical Pharmacology. LXXVI. Current progress in the mammalian TRP ion channel family.

Authors:  Long-Jun Wu; Tara-Beth Sweet; David E Clapham
Journal:  Pharmacol Rev       Date:  2010-09       Impact factor: 25.468

Review 2.  TRPM3_miR-204: a complex locus for eye development and disease.

Authors:  Alan Shiels
Journal:  Hum Genomics       Date:  2020-02-18       Impact factor: 4.639

3.  Quantitative high-throughput screening for chemical toxicity in a population-based in vitro model.

Authors:  Eric F Lock; Nour Abdo; Ruili Huang; Menghang Xia; Oksana Kosyk; Shannon H O'Shea; Yi-Hui Zhou; Alexander Sedykh; Alexander Tropsha; Christopher P Austin; Raymond R Tice; Fred A Wright; Ivan Rusyn
Journal:  Toxicol Sci       Date:  2012-01-19       Impact factor: 4.849

4.  Deletion of KDM6A, a histone demethylase interacting with MLL2, in three patients with Kabuki syndrome.

Authors:  Damien Lederer; Bernard Grisart; Maria Cristina Digilio; Valérie Benoit; Marianne Crespin; Sophie Claire Ghariani; Isabelle Maystadt; Bruno Dallapiccola; Christine Verellen-Dumoulin
Journal:  Am J Hum Genet       Date:  2011-12-22       Impact factor: 11.025

Review 5.  From enhanceropathies to the epigenetic manifold underlying human cognition.

Authors:  Alessandro Vitriolo; Michele Gabriele; Giuseppe Testa
Journal:  Hum Mol Genet       Date:  2019-11-21       Impact factor: 6.150

6.  Genomic imbalances detected by array-CGH in patients with syndromal ocular developmental anomalies.

Authors:  Andrée Delahaye; Pierre Bitoun; Séverine Drunat; Marion Gérard-Blanluet; Nicolas Chassaing; Annick Toutain; Alain Verloes; Frédérique Gatelais; Marie Legendre; Laurence Faivre; Sandrine Passemard; Azzedine Aboura; Sophie Kaltenbach; Samuel Quentin; Céline Dupont; Anne-Claude Tabet; Serge Amselem; Jacques Elion; Pierre Gressens; Eva Pipiras; Brigitte Benzacken
Journal:  Eur J Hum Genet       Date:  2012-01-11       Impact factor: 4.246

7.  Pregnenolone sulphate- and cholesterol-regulated TRPM3 channels coupled to vascular smooth muscle secretion and contraction.

Authors:  Jacqueline Naylor; Jing Li; Carol J Milligan; Fanning Zeng; Piruthivi Sukumar; Bing Hou; Alicia Sedo; Nadira Yuldasheva; Yasser Majeed; Dhananjay Beri; Shan Jiang; Victoria A L Seymour; Lynn McKeown; Bhaskar Kumar; Christian Harteneck; David O'Regan; Stephen B Wheatcroft; Mark T Kearney; Clare Jones; Karen E Porter; David J Beech
Journal:  Circ Res       Date:  2010-04-01       Impact factor: 17.367

8.  A family with autism and rare copy number variants disrupting the Duchenne/Becker muscular dystrophy gene DMD and TRPM3.

Authors:  Alistair T Pagnamenta; Richard Holt; Mohammed Yusuf; Dalila Pinto; Kirsty Wing; Catalina Betancur; Stephen W Scherer; Emanuela V Volpi; Anthony P Monaco
Journal:  J Neurodev Disord       Date:  2011-02-12       Impact factor: 4.025

9.  Mutation of the TRPM3 cation channel underlies progressive cataract development and lens calcification associated with pro-fibrotic and immune cell responses.

Authors:  Yuefang Zhou; Thomas M Bennett; Alan Shiels
Journal:  FASEB J       Date:  2021-02       Impact factor: 5.834

10.  Mutation of the melastatin-related cation channel, TRPM3, underlies inherited cataract and glaucoma.

Authors:  Thomas M Bennett; Donna S Mackay; Carla J Siegfried; Alan Shiels
Journal:  PLoS One       Date:  2014-08-04       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.